It has been shown in various mammal species that clonidine, a well known centrally acting hypotensive agent, acts through the activation of imidazoline receptors (IRs) in the nucleus reticularis lateralis (NRL) of the brainstem. Specific binding sites sensitive to imidazolines and insensitive to catecholamines have been detected in rat and bovine, as well as human brains. An endogenous ligand, other than catecholamines, should exist for these IRs. Such a ligand could play a role in the pathophysiology of human essential hypertension. Therefore, we developed two RIAs with polyclonal and monoclonal anticlonidine antibodies. These antibodies presented specificity spectra similar to that of the IRs: they bound imidazolines and not catecholamines at all. These RIAs were used to detect imidazoline-like immunoreactivity in the human serum. Immunoreactive substance was measured in 26 normotensive subjects' sera, and specificity of interaction between antibodies and sera was verified. None of the known endogenous substances tested so far were able to interact with the two antibodies. Immunoreactivity in 32 essential hypertensive patients' sera proved higher in -30% of cases. Values of immunoreactivity positively correlated with the mean arterial pressure values. This study demonstrates the existence of an "imidazoline-like" immunoreactive substance in the human serum with high levels in some hyper-
Introduction
Clonidine is a well known, centrally acting hypotensive substance that was described as an a2-adrenoceptor agonist. However, recently, animal investigations concerning the mechanism of the hypotensive effect of clonidine have led to the discovery of a new class ofreceptors: the imidazoline receptors (IR).I The demonstration of the existence of these IRs and 1 . Abbreviations used in this paper: CDS, clonidine-displacing substance; IR, imidazoline receptor; ng pac eq, nanogram para-aminoclonidine equivalent; NRL, nucleus reticularis lateralis; pac, paraaminoclonidine.
their involvement in the central control ofblood pressure were based on the following observations:
(a) in rats, clonidine hypotensive effect originates in the nucleus reticularis lateralis region in the brainstem ( 1 ); (b) catecholamines stereotaxically injected into this region never affected arterial pressure, in contrast with imidazolines, -which were hypotensive whatever their selectivity for alphaadrenoceptor subtypes (2); (c) in vivo electrochemical experiments performed in rats, confirmed that the clonidine hypotensive effect originating in the NRL region was related to imidazoline specific receptors and that sedation, the main side effect of clonidine, was due to activation of alpha2-adrenoceptors elsewhere in the brainstem, namely, the locus coeruleus (3);
(d) binding experiments with [3H]clonidine and [3H]
para-aminoclonidine (pac) also confirmed besides a classical a2-adrenergic binding of these ligands, the existence of specific imidazoline binding sites insensitive to catecholamines both in the brain and in peripheral tissues of various species, including humans, the hypotensive effect ofimidazolines being related to the specific imidazoline binding (4) (5) (6) ; (e) biochemical experiments( 7) permitted physical separation of alpha-adrenoceptors and imidazoline specific binding sites leading to the conclusion that they should be considered as two different molecular entities, at least within the rabbit kidney.
As these IRs are present in the human brain (4), one could assume that a noncatecholamine endogenous ligand could exist also in humans. And if IRs are involved in the regulation of cardiovascular tone in humans as it is in animals, it could therefore also be assumed that a dysfunctioning ofthe "imidazoline receptor system," concerning the receptor itself, or its endogenous ligand or both, might be associated with certain forms of essential hypertension. In fact, one could suppose that the endogenous ligand of IRs may share certain structural analogies with imidazolines. To test the presence ofendogenous imidazoline-like substances, we developed polyclonal and monoclonal antibodies against clonidine with para-aminoclonidine (pac) coupled to hemocyanine as the antigen (8, 9) . As was the case with IRs, these two antibodies bound imidazoline molecules and not catecholamines at all.
We have reported elsewhere that these antibodies were able to detect immunoreactive substances in bovine brain extracts (polyclonal antibodies; reference 8) and in human brain extracts (monoclonal antibody mFE7; reference 9) containing the putative endogenous ligand for IRs.
Here we compare two radioimmunoassays developed with the polyclonal and monoclonal antiimidazolines antibodies to detect circulating immunoreactive substances in human sera from normotensive and hypertensive subjects.
Methods
Antibody preparation. Preparation of polyclonal antibodies has been described elsewhere (8) . Briefly, para-aminoclonidine linked to hemocyanin with glutaraldehyde was injected into rabbits. The resulting specific antisera were characterized: the polyclonal antibodies recognized imidazolines closely related to clonidine and no known endogenous substances tested.
Monoclonal antibody (mFE7) production and characterization has been described elsewhere (9) . Despite a lower affinity for free pac and clonidine than the polyclonal antibodies, the specificity was similar: mFE7 recognized iminoimidazolidines and no catecholamines or other known endogenous substances tested.
Subjects and patients. Essential hypertensive patients and normotensive subjects were investigated in this study.
Serum (15) (16) (17) (18) (19) (20) Sample preparation. All the samples tested in this study were prepared without any blood-clotting inhibitors and after fasting (10 h). All the sera were stored frozen at -20°C until used (4-8 wk). Subsequently, sera were thawed and ultrafiltered through membranes (YM1-MW cutoff, 1,000 D-level; Amicon Div., W. R. Grace, Inc., Beverly, MA) at 4°C. Membranes were washed with 10 ml ultrapure water, and resulting dialysates lyophilized. The dry powder obtained was methanol extracted three times with decreasing volumes of methanol (4,2,1 ml; RCS 10-60; Jouan, Paris). The methanol soluble fractions were evaporated to dryness in a speedvac, reconstituted in 5 ml of ultrapure water, and stored at -20°C until analysis by radioimmunoassays described below. Serum 
Results
Sensitivity ofradioimmunoassays. Typical calibration curves, generated according to the proposed protocol, are shown in Fig. 1 .
The RIA procedures appeared to be most suitable for the detection of pac levels in the range from 0.25 to 10 ng/ 100 pl for polyclonal antibodies and from 5 to 100 ng/ 100 gl for the monoclonal antibody. Thus, the polyclonal RIA appeared about ten times more sensitive than the monoclonal RIA, due to the higher affinity of polyclonal antibodies for free pac (Kd = 13 nM) compared to monoclonal antibodies (Kd = 180 nM). Immunoreactivity in the human samples. In the serum extracts of normotensive subjects, immunoreactivity was detectable at low level (Fig. 2, lines 1 and 3 ) with the two radioimmunoassays. Mean values (mean±SD) of immunoreactivity were 7.6±12.1 ng pac eq/ml (n = 26) with monoclonal antibodies and 1 1.9±19.2 ng pac eq/ml (n = 26) with polyclonal antibod- The results are expressed as ng pac eq/ml serum, calculated by extrapolation of standard curves as described in Methods. Results are the mean of at least three determinations at two dilutions of serum extracts in triplicate.
ies. The ranges of values were respectively 0 to 48.7 ng pac eq/ml and 0 to 74.3 ng pac eq/ml.
However, significant differences with these values were noted in the hypertensive group. As can be seen in Fig. 2 (Fig. 4) and r = 0.39, P < 0.01 for monoclonal RIA.
Heart rates ofpatients with high levels of immunoreactivity were not significantly different (P = 0.54) from those with low levels: 69.1±11.0 beats/min (mean±SD, n = 9) and 71.4±9.3 beats/min (mean+SD, n = 23), respectively. (12) (13) (14) (15) . Assays with these antibodies were conducted as usually described for drug-specific RIAs: (a) accuracy was determined with biological fluids (serum, urine) with added known levels of drugs; (b) so-called "matrix effects" were abolished in the assays by dilutions of analytical samples in biological fluids identical to those used for calibration curves, except that they were drug free; (c) specificity of RIAs was generally assessed by determining cross-reactivities of drug metabolites; (d) pharmacokinetics in human plasma were studied after oral or intravenous administration of clonidine. In contrast, data presented in this paper only concern clonidine-or clonidine-like drug-free subjects, and thus concern clonidine-free serum samples. Even in the absence of clonidine and clonidine-like drugs, both polyclonal and monoclonal anticlonidine antibodies detected immunoreactivity in human serum.
What is the nature of the substances responsible for this immunoreactivity? Several criteria have been tested to assess the specificity of the interaction between fluid extracts and the antibodies. Linearity of results obtained with serial dilutions of samples, as well as parallelism observed between standard curves and sample curves, showed that the interactions of pac and endogenous substance with antibodies are similar. In addition, serum extracts that have been supplemented with pac gave a curve that was superimposable on the pac standard curve when corrected for endogenous immunoreactivity. Despite slightly different specificity spectra, the two different antibodies gave the same qualitative and quantitative results. As the material used in this study was oflimited purity, we cannot exclude the possibility that known biological substances are recognized by the antibodies. Therefore, to determine specificity spectra of our two antibodies, we focused our attention on endogenous substances present in human serum and potentially capable ofinteracting with pac binding on the antibodies. As shown elsewhere (8) , catecholamines (noradrenaline, adrenaline, dopamine) and their metabolites (DOPAC, DO-PEG, dihydroxymandelic acid) as well as histamine, purine, adenine, and adenosine were unable to cross-react with polyclonal antibodies. We recently completed that list with arginine, guanidine, guanosine, carnosine, histidine, and tyrosine that all were ineffective on pac binding on the antibodies. Similarly, monoclonal antibody mFE7 specificity has been reported elsewhere (9) and showed the same results. All known endogenous substances we have so far tested with the two antibodies appeared without effect in the RIA described here. ( 12) demonstrated that salicylic acid decreased the sensitivity of an immunological assay of clonidine. Our first group of sera was provided by healthy normotensive donors. Despite the fact that they received no medication, a basal level ofimmunoreactivity was observed with both antibodies. None of the hypertensive patients received any antihypertensive treatment. Associated treatments consisted essentially ofbenzodiazepine anxiolytics, and no drugs had structural analogies with imidazolines. We have at the present time no evidence that immunoreactivity observed in the serum could be attributed to nonspecific interaction in the RIAs.
The chemical nature of the substance present in the serum is, for the moment, unknown, but some indications can be drawn from the method of preparation of serum extracts. The immunoreactive substance appears not to be a protein: it has a molecular mass < 1,000 D, it is methanol-and water-soluble, and its structure must be related to that of clonidine or paraaminoclonidine according to the strict specificity of the antibodies used in this study.
The plasma level ofthe imidazoline-like immunoreactivity was much higher in some patients with essential hypertension receiving no antihypertensive treatment. The immunoreactivity could reach levels as high as ten times the values observed in normotensive subjects. High levels ofthe immunoreactive substance were observed in -30% of the hypertensive patients. One can assume that, since some borderline hypertensives were included in the group of hypertensive patients, this percentage was even underestimated.
We did not observe differences between heart rate values among the groups of patients whether they exhibited high or low immunoreactivities. These results seem to indicate that the autonomic nervous system activities in both groups ofpatients were similar. The correlation between mean arterial pressure and immunoreactivity is particularly interesting; an abnormal high serum level ofthis substance might therefore be associated with certain forms of the so-called essential hypertension. The presence of high serum level of clonidine-like substances has also been described in pregnancy-induced hypertension ( 16) .
The question remains whether the immunoreactive substance detected with anticlonidine antibodies and the putative endogenous ligand for IRs are identical. Indirect evidences argue in favor of this hypothesis. (a) Specificities of our antibodies are limited to imidazoline-containing substances; (b) the two antibodies we used proved capable to detect immunoreactivity in bovine and human brain extracts containing the putative endogenous ligand of IRs; (c) an immunoreactive compound supposed to be a CDS (clonidine-displacing substance)-like substance was detected with polyclonal anticlonidine antibodies in rat serum extracts and proved able to contract rat gastric fundus smooth muscle (17) ; (d) Synetos et al. (18) reported the presence ofCDS, supposed to contain the endogenous ligand of IRs, in human serum. Only the purification of both the endogenous ligand to IRs and the imidazoline-like immunoreactive circulating substance will provide an unequivocal proof of their identity.
Biological effects of CDS, related to vasomotor tone, have been described: it proved hypertensive in animal models ( 19) and contracted blood vessels in a dose-dependent manner (18) .
Thus, if the substance we detected with higher circulating levels in some hypertensive patients is related to CDS, then this one might contribute to maintain an elevated arterial pressure and clonidine-like drugs might therefore be antihypertensive through inhibition ofthe CDS effects. Again, the complete purification of these compounds will clarify this point.
